Skip to main content
Premium Trial:

Request an Annual Quote

LifeCodexx, Elucigene Diagnostics Partner to Offer NIPT in UK and Ireland

NEW YORK (GenomeWeb) – LifeCodexx and Elucigene Diagnostics said today that they have partnered to make LifeCodexx's noninvasive prenatal screening test, PrenaTest, available to patients in the UK and Ireland.

Konstanz, Germany based-LifeCodexx launched PrenaTest based on technology it licensed from Sequenom in 2012 and has made the test available throughout Europe. Elucigene Diagnostics, based in Manchester, UK, is a developer and distributor of prenatal and human genetic diagnostics.

Mark Street-Docherty, commercial manager of Elucigene Diagnostics, said in a statement that offering LifeCodexx's PrenaTest "complements our continued support for prenatal testing accuracy."

PrenaTest is now available in more than 40 countries throughout Europe and the Middle East, Michael Lutz, CEO of LifeCodexx, noted in a statement.

Earlier this year, LifeCodexx inked deals with partner labs in Germany and Switzerland for the test.

The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.